Genentech, Blueprint tout full approval for Gavreto in rare type of lung cancer

Genentech and Blueprint Medicines scored a full FDA approval on Wednesday for Gavreto’s use in a small subset of non-small cell lung cancer patients, nearly three years after celebrating an initial win via the accelerated approval pathway.

Gavreto, also known as pralsetinib, was approved in September 2020 for adults…
Click here to view original post